Stefano Persiani

Summary

Publications

  1. ncbi Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose
    S Persiani
    Rotta Research Laboratorium Rottapharm, Monza, Italy
    Osteoarthritis Cartilage 15:764-72. 2007
  2. ncbi In vitro study of the inhibition and induction of human cytochromes P450 by crystalline glucosamine sulfate
    Stefano Persiani
    Rottapharm SpA, Monza, Italy
    Drug Metabol Drug Interact 24:195-209. 2009
  3. ncbi Glucosamine binding to proteins in plasma and synovial fluid and blood cell/plasma partitioning in mouse and man in vitro
    Stefano Persiani
    Rottapharm SpA, Monza, Italy
    Drug Metabol Drug Interact 24:211-27. 2009
  4. ncbi Pharmacokinetic profile of dexloxiglumide
    Stefano Persiani
    Departments of Clinical Pharmacology and Drug Metabolism, Pharmacokinetics and Dynamics, Rotta Research Laboratorium Rottapharm, Monza, Italy
    Clin Pharmacokinet 45:1177-88. 2006
  5. ncbi Strategies to assess the drug interaction potential in translational medicine
    Stefano Persiani
    Department of Drug Metabolism, Pharmacokinetics and Dynamics, Rottapharm SpA, Via Valosa di Sopra, 7, 20052 Monza, MI, Italy
    Expert Opin Drug Metab Toxicol 2:675-86. 2006

Detail Information

Publications5

  1. ncbi Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose
    S Persiani
    Rotta Research Laboratorium Rottapharm, Monza, Italy
    Osteoarthritis Cartilage 15:764-72. 2007
    ..We investigated the synovial and plasma glucosamine concentrations in osteoarthritic patients following oral administration of crystalline glucosamine sulphate at the therapeutic dose of 1500mg once-a-day for 14 days...
  2. ncbi In vitro study of the inhibition and induction of human cytochromes P450 by crystalline glucosamine sulfate
    Stefano Persiani
    Rottapharm SpA, Monza, Italy
    Drug Metabol Drug Interact 24:195-209. 2009
    ..Therefore, no clinically relevant metabolic interactions are expected between CGS and co-administered drugs that are substrates of the CYP enzymes investigated...
  3. ncbi Glucosamine binding to proteins in plasma and synovial fluid and blood cell/plasma partitioning in mouse and man in vitro
    Stefano Persiani
    Rottapharm SpA, Monza, Italy
    Drug Metabol Drug Interact 24:211-27. 2009
    ..No corrections are needed, either for unbound fraction when comparing human and mouse pharmacokinetic data or for blood cell/plasma partitioning to assess glucosamine total blood clearance from plasma data in these two species...
  4. ncbi Pharmacokinetic profile of dexloxiglumide
    Stefano Persiani
    Departments of Clinical Pharmacology and Drug Metabolism, Pharmacokinetics and Dynamics, Rotta Research Laboratorium Rottapharm, Monza, Italy
    Clin Pharmacokinet 45:1177-88. 2006
    ..The results of different drug interaction studies have indicated that no clinically relevant metabolic and concomitant drug-drug interactions are expected during the clinical use of dexloxiglumide...
  5. ncbi Strategies to assess the drug interaction potential in translational medicine
    Stefano Persiani
    Department of Drug Metabolism, Pharmacokinetics and Dynamics, Rottapharm SpA, Via Valosa di Sopra, 7, 20052 Monza, MI, Italy
    Expert Opin Drug Metab Toxicol 2:675-86. 2006
    ....